Nicolino Ruperto
Istituto Giannina Gaslini
Quality of lifeJuvenileInternal medicineSurgeryPhysical therapyPediatricsRheumatologyPlaceboArthritisDiseaseJuvenile rheumatoid arthritisMethotrexateJuvenile Arthritis Disease Activity ScoreMultidimensional assessmentFunctional abilitySeverity of illnessDisease statusClinical trialMedicineGerontology
311Publications
82H-index
17.4kCitations
Publications 307
Newest
#1Chiara Trincianti (UniGe: University of Genoa)
#2Evert Hendrik Pieter van Dijkhuizen (Istituto Giannina Gaslini)H-Index: 3
Last. Pierre Quartier (Necker-Enfants Malades Hospital)H-Index: 64
view all 21 authors...
OBJECTIVE To develop and validate new Juvenile Arthritis Disease Activity Score 10 (JADAS10) and clinical JADAS10 (cJADAS10) cutoffs to separate the states of inactive disease (ID), minimal disease activity (MiDA), moderate disease activity (MoDA), and high disease activity (HDA) in children with oligoarthritis and with rheumatoid factor-negative polyarthritis, based on subjective disease assessment by the treating pediatric rheumatologist. METHODS The cutoffs definition cohort was composed of 1...
1 CitationsSource
#1Joeri W van Straalen (Boston Children's Hospital)
#2Roline Krol (Boston Children's Hospital)H-Index: 1
Last. Despoina Maritsi (UoA: National and Kapodistrian University of Athens)H-Index: 6
view all 22 authors...
Objectives null To describe risk factors for inflammatory bowel disease (IBD) development in a cohort of children with juvenile idiopathic arthritis (JIA). null Methods null JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different disease-modifying anti-rheumatic drugs (...
Source
#1Hermine I. Brunner (Cincinnati Children's Hospital Medical Center)H-Index: 57
#2Carlos Abud-Mendoza (Universidad Autónoma de San Luis Potosí)H-Index: 31
Last. Fengchun Zhang (Peking Union Medical College Hospital)H-Index: 44
view all 18 authors...
Objective null To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE). null Methods null We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupu...
Source
#2Jens KlotscheH-Index: 47
Last. Mark LuntH-Index: 88
view all 20 authors...
OBJECTIVES Burden of comorbidities are largely unknown in JIA. From 2000, national and international patient registries were established to monitor biologic treatment, disease activity and adverse events in patients with JIA. The aim of this analysis was to investigate in parallel, for the first time, three of the largest JIA registries in Europe/internationally-UK JIA Biologic Registers (BCRD/BSPAR-ETN), German biologic registers (BiKeR/JuMBO), multinational Pharmachild-to quantify the occurren...
Source
#1Hermine I. Brunner (Cincinnati Children's Hospital Medical Center)H-Index: 57
#2Chen Chen (Cincinnati Children's Hospital Medical Center)H-Index: 10
Last. Nicolino Ruperto (Istituto Giannina Gaslini)H-Index: 82
view all 19 authors...
OBJECTIVE Evaluate changes in health-related quality of life (HRQOL) and disability in children with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA) treated with tocilizumab. METHODS Secondary analyses of two double-blind, placebo-controlled trials of intravenous tocilizumab in children with active sJIA or pJIA were conducted. Patient-reported outcomes of disability (Childhood Health Assessment Questionnaire [CHAQ]), HRQOL (Child Health Questio...
Source
#1Marta Bustaffa (Istituto Giannina Gaslini)H-Index: 1
#2Francesca Mazza (UNIME: University of Messina)H-Index: 1
view all 34 authors...
Source
#1Nicolino Ruperto (Istituto Giannina Gaslini)H-Index: 82
#2Alberto Martini (UniGe: University of Genoa)H-Index: 106
Last. Angela Pistorio (Istituto Giannina Gaslini)H-Index: 73
view all 3 authors...
Until the end of the last century there were no drugs approved for the treatment of juvenile idiopathic arthritis (JIA). This situation was revolutionized in the past 20 years thanks to 3 factors: the introduction in the USA and in Europe of paediatric legislations(1, 2), the availability of biologic disease-modifying anti-rheumatic drugs (b-DMARDs), and the existence of not-for-profit organizations with the mission to foster, facilitate and co-ordinate the development, conduct, analysis, and re...
Source
#1Joeri W van Straalen (Boston Children's Hospital)
#2Gabriella Giancane (Istituto Giannina Gaslini)H-Index: 10
Last. Joost F Swart (Boston Children's Hospital)H-Index: 11
view all 19 authors...
Objective To build a prediction model for uveitis in children with JIA for use in current clinical practice. Methods Data from the international observational Pharmachild registry were used. Adjusted risk factors as well as predictors for JIA-associated uveitis (JIA-U) were determined using multivariable logistic regression models. The prediction model was selected based on the Akaike information criterion. Bootstrap resampling was used to adjust the final prediction model for optimism. Results ...
Source
#1Silvia RosinaH-Index: 6
#2Giulia Camilla Varnier (Boston Children's Hospital)H-Index: 8
Last. Angelo RavelliH-Index: 90
view all 20 authors...
OBJECTIVE To develop and test shortened versions of the Manual Muscle Test-8 (MMT-8) in juvenile dermatomyositis ( JDM). METHODS Construction of reduced tools was based on a retrospective analysis of individual scores of MMT-8 muscle groups in 3 multinational datasets. The 4 and 6 most frequently impaired muscle groups were included in MMT-4 and MMT-6, respectively. Metrologic properties of reduced tools were assessed by evaluating construct validity, internal consistency, discriminant ability, ...
1 CitationsSource
#1Peter A. Nigrovic (Brigham and Women's Hospital)H-Index: 50
#2Robert A. Colbert (NIH: National Institutes of Health)H-Index: 53
Last. Alberto Martini (UniGe: University of Genoa)H-Index: 106
view all 9 authors...
1 CitationsSource